Skip to main content
Equibles
PLX logo

PLX · Protalix BioTherapeutics, Inc. · Metrics

Track PLX — free

Use PLX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.64 -0.09 (-3.30%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$212.71M
Shares
80.57M

PLX metrics

72 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.64
Market cap
$212.71M

Price action

20 metrics
Price change (1W)
+4.2%
Price change (30D)
+15.7%
Price change (3M)
+33.2%
Price change (6M)
-2.2%
Price change (YTD)
+51.7%
Price change (1Y)
+61.5%
Trailing year
Price change (5Y)
+82.0%
52-week high
$3.15
52-week low
$1.67
Change from 52-week high
-13.3%
Change from 52-week low
+63.5%
Annualized volatility
63.5%
Annualized volatility (3M)
46.2%
Beta
1.3
RSI (14D)
68.1
Price vs SMA 50
+12.7%
Price vs SMA 200
+20.9%
Avg volume (3M)
697,717
Relative volume
1.1
Average dollar volume
$1.67M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
80.57M

Valuation

12 metrics
P / E (TTM)
11.4
Trailing earnings · reciprocal yield 8.8%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.7×
reciprocal yield 36.7%
P / book
3.1
reciprocal yield 32.5%
FCF yield
3.5%
TTM · current market cap
Buyback yield
—
P / FCF
28.7
reciprocal yield 3.5%
P / operating cash flow
22.2
reciprocal yield 4.5%
Earnings yield
8.6%

Historical valuation

8 metrics
P / E historical average (3Y)
26.6×
reciprocal yield 3.8%
P / E historical average (5Y)
26.6×
reciprocal yield 3.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
28.9%
Trailing 12 months
Net margin
23.5%
Gross profit (TTM)
$1.11M
Operating profit (TTM)
$23.29M
Net income (TTM)
$18.95M
Trailing 12 months
Diluted EPS (TTM)
$0.24
FCF margin
9.5%
Effective tax rate
19.3%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.60

Growth

11 metrics
Revenue growth YoY
+27.1%
Year over year
Net income growth YoY
+2,203.0%
Revenue (TTM)
$80.62M
Trailing 12 months
EPS growth YoY
-300.0%
Shares change YoY
+1.6%
Year over year · more shares
Revenue CAGR (3Y)
+3.5%
Revenue CAGR (5Y)
-3.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
26.5%
Return on assets
17.2%
Debt / equity
—
Current ratio
2.9
EBITDA (TTM)
—
Free cash flow (TTM)
$7.67M
Quick ratio
1.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$27.42M
Total assets
$110.34M
Total debt
$912,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$9.92M
Capital expenditures (TTM)
$2.25M
R&D (TTM)
$19.88M
SG&A (TTM)
$12.62M
Stock compensation (TTM)
$2.26M
R&D / revenue
24.7%
Stock compensation / revenue
2.8%

Ownership (13F)

3 metrics
13F filers
101
13F filer change QoQ
0
Institutional ownership
18.4%

Short interest

3 metrics
Short interest
3.9%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1006281 CUSIP 74365A309 13F (30d) 41 filings 41 filers Visit website Investor relations